Abstract: OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). METHODS: Patient charts and our prospective ASCT database were assessed for the impact of documented variables on event free survival (EFS) and overall survival (OS), including salvage and conditioning regimens used, and PET/CT results before and after ASCT. RESULTS: Overall, 180 patients with NHL (n = 134; 74%) or HL (n = 46; 26%) received ASCT from December 2000 to May 2011. Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). Conditioning was mainly performed with cyclophosphamide, carmustine, etoposide (CBV) (n = 72; 40%) or carmustine, etoposide, cytarabine, melphalan (BEAM) (n = 103; 57%). Treatment-related mortality (TRM) was 1.7%. Outcome data are in line with previously reported studies, especially the data for salvage treatment and BEAM conditioning in DLBCL patients confirmed the outcome reported recently in a phase III study. Positive pre-and post-transplantation PET/CT was an adverse risk factor for survival (PET/CT+ before ASCT: hazard ratio (HR): 2.65 (1.11−6.33), p = 0.029; PET/CT+ after ASCT: HR: 7.11 (2.76−18.34), p <0.0001). Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. CONCLUSIONS: Conditioning with CBV or BEAM and subsequent ASCT was feasible and effective. Initial lymphoma stage and number of previous treatment lines were identified as independent risk factors for EFS in DLBCL and HL patients. Summary OBJECTIVE: To assess the prognostic value of various parameters including positron emission tomography / computed tomography (PET/CT) and identify risk factors for survival of patients with non-Hodgkin's lymphoma (NHL) and Hodgkin's lymphoma (HL) treated with autologous stem cell transplantation (ASCT). METHODS: Patient charts and our prospective ASCT database were assessed for the impact of documented variables on event free survival (EFS) and overall survival (OS), including salvage and conditioning regimens used, and PET/CT results before and after ASCT. RESULTS: Overall, 180 patients with NHL (n = 134; 74%) or HL (n = 46; 26%) received ASCT from December 2000 to May 2011. Of the NHL patients, 59 (44%) had diffuse large B-cell lymphoma (DLBCL). Conditioning was mainly performed with cyclophosphamide, carmustine, etoposide (CBV) (n = 72; 40%) or carmustine, etoposide, cytarabine, melphalan (BEAM) (n = 103; 57%). Treatment-related mortality (TRM) was 1.7%. Outcome data are in line with previously reported studies, especially the data for salvage treatment and BEAM conditioning in DLBCL patients confirmed the outcome reported recently in a phase III study. Positive pre-and post-transplantation PET/CT was an adverse risk factor for survival (PET/ CT+ before ASCT: hazard ratio (HR): 2.65 (1.11−6.33), p = 0.029; PET/CT+ after ASCT: HR: 7.11 (2.76−18.34), p <0.0001). Other risk factors for survival were primary refractory disease, initial lymphoma stage, number of previous chemotherapy lines, and high amounts of blood product transfusions. CONCLUSIONS: Conditioning with CBV or BEAM and subsequent ASCT was feasible and effective. Initial lymphoma stage and number of previous treatment lines were identified as independent risk factors for EFS in DLBCL and HL patients. 
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Introduction
High-dose chemotherapy (HDC) followed by autologous stem cell transplantation (ASCT) is being widely used as salvage treatment in patients with non-Hodgkin's lymphoma (NHL) or Hodgkin's lymphoma (HL) [1] [2] [3] . This treatment strategy has the potential to improve significantly survival compared with standard dosed salvage chemotherapy alone. It offers a chance for a cure in up to 50% of patients with chemosensitive relapse, while the results are still unsatisfactory in patients with primary refractory disease, where a cure rate of 10%-25% may be achieved [4, 5] ; an important prognostic factor for survival is the response to salvage chemotherapy. Patients with complete remission (CR) before ASCT have a better survival than patients with partial remission (PR) [6, 7] . In addition, many centres offer HDC and ASCT also as consolidation treatment after first line therapy to patients with poor prognostic features, i.e., in patients with T cell lymphoma or primary central nervous system lymphoma. The autologous stem cell transplantation programme Zurich includes two hospitals, the University Hospital and the Triemli City Hospital. It was initiated in 1988, and we reported first results 11 years later after having performed more than 250 ASCTs, predominantly in patients with NHL, HL, multiple myeloma and germ cell tumours [8] . Recently, we reported our current results in patients with multiple myeloma, who received ASCT as consolidation treatment. Beside survival data comparable to published data, we observed minimal toxicity and a low treatment related mortality (TRM) of 0.5% [9] . Treatment modalities for HL and NHL have changed during the last 10 years owing to various improvements in this field; the possibility of harvesting peripheral blood stem cells omits the invasive bone marrow harvest procedure. The use of granulocyte-colony stimulating factors (G-CSF) reduces the time to engraftment and, thus, the risk of infectious complications during neutropenia [10, 11] . Patient management has also improved through implementation and continuous adjustment of international standard operating procedures. We retrospectively analysed the clinical course and the outcome of all patients with NHL and HL undergoing ASCT from December 2000 until May 2011 to identify possible risk factors for survival and to control for quality in comparison to published data. Further, we placed a special emphasis on the prognostic impact of positron emission tomography / computed tomography (PET/CT) before and after ASCT on treatment outcome.
Patients and methods

Patient data assessment
Patients with NHL and HL who received an ASCT at our transplantation centre were analysed retrospectively, based on a prospective transplantation database. This analysis was approved by our local ethics committee.
Data regarding lymphoma stage, the salvage and conditioning regimens used, the response to treatment before and after ASCT, event free survival (EFS) and overall survival (OS) were collected. Additional variables like age, gender, body mass index (BMI), the amount of cluster of differentiation (CD) 34 positive cells mobilised, and PET/CT results were documented. We also collected data regarding the haematological toxicity and the supportive care of the patients during the post-transplant phase.
Treatment
All patients received primary salvage chemotherapy as chosen by the attending oncologists. Salvage regimens used were ICE (ifosfamide, carboplatin, etoposide), DHAP (dexamethasone, cytarabine, cisplatin), EPOCH (prednisone, doxorubicine, vincristine, etoposide, cyclophosphamide), Dexa-BEAM (dexamethasone, carmustine, etoposide, cytarabine, melphalan) or CHOP-like (prednisone, cyclophosphamide, doxorubicin, vincristine) regimens. Stem cell mobilisation was usually performed after the second or third treatment cycle by administering daily filgrastim at a dose of 10 μg/kg body weight from day -3 on. Apheresis was performed at our transplantation centre until at least 2 x 10 6 CD34+ cells per kilogramme body weight were collected. Purging was not part of the procedure. The collected cell products were cryopreserved with 10% dimethyl sulfoxide (DMSO) and stored in liquid nitrogen until the day of ASCT. Cell thawing was performed immediately before retransfusion in a 37 °C water bath. . Patients with poor performance status, organ dysfunctions like renal insufficiency, reduced pulmonary diffusion capacity or age over 65 years could receive a reduced dose of etoposide and/ or carmustine after discussion in our multidisciplinary transplantation board. As previously reported patients received daily filgrastim at a dose of 5 μg/kg body weight from day +5 on or pegfilgrastim 6 mg once on day +1 after ASCT to shorten time to engraftment [12] . Regarding the management of febrile neutropenia after ASCT, we comply with general European guidelines at our centre [13] . Briefly, patients received empiric broad spectrum antibiotic therapy with Pseudomonas-active β-lactam agents (like piperacillin-tazobactam or cefepime in first, carbapenems in second line). In case of obvious infections with gram-positive germs (i.e., catheter-infection) the patients also received vancomycin. According to international guidelines, the transfusion threshold after ASCT for patients with anaemia was haemoglobin of 7 g/dl (or higher in case of associated symptoms or cardiovascular disease), and for patients with thrombocytopenia thrombocyte levels of 10 x 10 9 /L (20 x 10 9 /L for patients with increased risk of bleeding) [14, 15] .
Response criteria
Assessment of disease response was based on every available clinical or radiological evaluation, including PET/CT, as documented in the patient charts and the radiologic reports. Because of the low patient numbers, we only discriminated between patients with CR or unconfirmed CR (CRu), and patients with less than CR. EFS was defined as time from ASCT to the time of first recurrence after achievement of CR or to the time of progression in patients with unconfirmed CR, as verified by clinical examination, imaging and biopsy, or to the time of death by any cause. OS was defined as time from ASCT to the time of death by any cause, as documented in the patient charts.
Assessment of PET-response 2-[fluorine-18]-fluoro-2-deoxy-D-glucose
(FDG)-PET imaging data were acquired on a combined PET/CT inline system (Discovery LS, RX or Discovery STE; GE Health Systems, Milwaukee, WI). This technique allowed the combination of CT-scans and PET images in a single session. PET/CT was available since 2001 at our institution, and has been increasingly used for staging and treatment monitoring of lymphoma patients during and after end of treatment. It was used individually at the treating physician's discretion, and therefore PET data are not available for all patients. PET/CT scans performed during or after completion of salvage chemotherapy (pre-ASCT PET/CT) and within three months after ASCT (post-ASCT PET/CT) were evaluated. Image analysis was routinely carried out by two nuclear radiology physicians in consensus. PET/CT scans were assessed for residual pathologic FDGuptake.
Statistics
Descriptive statistics (median and range, or counts) were calculated for all variables. Event free and overall survival were calculated from the date of ASCT, and censored at the date of last follow-up. Survival curves were computed us- 
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Swiss Med Wkly. 2013;143:w13791 ing the method of Kaplan and Meier, and compared using the log-rank test [16] . Risk factor analysis for survival was performed by univariate Cox proportional hazards models and multivariate Cox regression models. P-values <0.05 were considered statistically significant. All analyses were performed in the R programming language [17] .
Results
Patient demographics
Between December 2000 and May 2011, a total of 180 consecutive ASCTs were performed in lymphoma patients at our centre. Of these patients, 59 (32%) were diagnosed with diffuse large B-cell lymphoma (DLBCL) and 46 (26%) with HL. About two-thirds were male (65%) and one-third female (35%). Eighty-seven (48%) received a PET/CT during or after salvage chemotherapy, and 63 (35%) also received PET/CT within 3 months after ASCT. In our patient cohort, 15% of DLBCL patients had received prior rituximab during previous treatment until 2006, while from 2007 on 93% of the DLBCL patients had already been pretreated with rituximab. Some of the patients had received first-line therapy at other hospitals or at oncological private practices before they were subsequently referred to our transplantation centre for salvage treatment and ASCT. The main patient characteristics are shown in table 1.
Treatment period
All clinical data is shown in 6 -20.1 x 10 6 ). The median duration of grade 4 neutropenia and the median time to engraftment were 8 days (range, 5-22 days) and 9 days (range, 7-23 days), respectively. The median duration of grade 4 thrombocytopenia was 6 days (range, 0-20 days). The number of CD34+ 1a, b) . The median length of hospital stay from the day of ASCT was 15 days (range, 9-72 days). Patients received a median of 2 units (range, 0-60) platelet transfusions and a median of 2 units (range, 0-43) red blood cell (RBC) transfusions during hospital stay. Fever developed in 160 (89%) patients after ASCT, and the use of antibiotics for therapeutic purposes was necessary in 169 (94%) patients during the post-transplant period. Bacterial pathogens were isolated in 46 (26%) patients. Infectious agents most commonly isolated were Klebsiella pneumoniae (n = 6; 3%), Escherichia coli (n = 10; 6%) and coagulase-negative Staphylococcus sp. (n = 13; 7%). Four (2%) patients died within the first 100 days after ASCT. One patient died due to disease progression, and the other three patients died due to infectious complications: one Pseudomonas aeruginosa septicaemia, one cytomegalovirus pneumonitis, and one Aspergillus fumigatus pneumonia. The TRM for the whole patient collective was 1.7%.
Original article
Swiss Med Wkly. 2013;143:w13791 stem cells correlated inversely with the duration of grade 4 thrombocytopenia (correlation coefficient r = -0.1815) and
Figure 2
Event free survival (A) and overall survival (B) of the patients with respect to the different lymphoma subgroups. MCL, mantle cell lymphoma; DLBCL, diffuse large B-cell lymphoma; HL, Hodgkin's lymphoma; TCL, T cell lymphoma.
Survival
Sufficient follow-up data was available for all patients except for one female patient, who was lost 53 days after ASCT. She was from abroad and came to Switzerland only for the ASCT procedure. The median follow-up was 31 months (range, 0.29-136 months). The median EFS and OS were not reached until the end of follow-up for the whole patient collective. OS differed between patients with DLBCL, HL, mantle cell lymphoma (MCL), follicular lymphoma (FL) and T-cell lymphoma (TCL) significantly (p <0.001). TCL patients had a worse prognosis compared with the other lymphoma subtypes. No statistically significant differences were seen regarding EFS ( fig. 2a, b) . The 3-year EFS was 67% for HL patients treated with CBV predominantly from 2000 to 2005, and 65% for HL patients treated with BEAM as conditioning regimen from 2006 on. The corresponding 3-year OS were 88% and 82%, respectively. No differences were seen in HL patients treated in the late period with BEAM compared with the early period with CBV regarding initial lymphoma stage, length of CR before relapse or patient age. For DLBCL patients, 3-year EFS was 76% in the early period, and 27% in the late period. The corresponding 3-year OS were 76% and 54%, respectively. The patients with DLBCL treated during the early period with CBV tended to be younger than Impact of chemosensitivity to primary chemotherapy on event free survival (A) and overall survival (B).
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Swiss Med Wkly. 2013;143:w13791 the DLBCL patients treated later with BEAM, although the difference did not reach statistical significance (p = 0.052). Patients with primary refractory disease had a statistically worse EFS and OS than patients with a relapse after response to initial treatment (3-year EFS 37% versus 63%, p = 0.0008; 3-year OS 55% versus 76%; p = 0.003) ( fig. 3a,  b) . In contrast, no statistically significant survival differences were seen regarding the disease status before ASCT (CR/CRu versus less than CR: 3-year EFS 60% versus 51%, p = 0.12; 3-year OS 72% versus 69%, p = 0.58). Also no statistically significant differences were seen with regard to the duration of remission before relapse or the use of rituximab during salvage treatment.
Response assessment with PET/CT and decisional impact
Overall, 39 (45%) of 87 patients with pre-ASCT PET/CT had residual FDG-uptake considered pathological. Patients with partial remission continued with their scheduled procedure, while patients with no response or progressive disease received a new non-crossresistant salvage treatment. Twenty (32%) of 63 patients with post-ASCT PET/CT had residual FDG-uptake considered pathological. As a consequence, six patients received short-term follow-up with PET/CT within 3 months, four patients immediately received new chemotherapy, and three patients received radiotherapy. One additional patient was planned for radiotherapy but died as a result of lymphoma progression before treatment could be initiated. Two patients had a biopsy that was negative, and one patient underwent a splenectomy. In three patients the positive post-ASCT PET/CT had no impact on the follow-up schedule; two of these patients remained in complete remission, while one patient relapsed at a later point. PET/CT performed after ASCT could detect relapses with a positive predictive value of 0.7.
A positive PET/CT during or after completion of salvage chemotherapy but before ASCT was associated with inferior EFS (HR 2. fig. 4c, d ).
In the patient subgroups with DLBCL and HL, only for the DLBCL patients a positive PET/CT before and after ASCT was associated with reduced EFS (both p <0.05), but not OS. No differences were observed for HL patients regarding PET/CT before ASCT. An analysis of the HL patient subgroup which had received PET/CT after ASCT was not possible due to the low number of events (figs 5 and 6). (table 5) .
Risk factor analysis
Discussion
To identify risk factors for overall and event-free survival we evaluated the outcome data of our NHL and HL patients treated with ASCT. The number of previous chemotherapy lines, the responsiveness to first line chemotherapy, the Table 3 : Conditioning regimens used according to lymphoma subtype.
BEAM CBV Other
Hodgkin's lymphoma -n (%) 22 (48) 24 ( HR = hazard ratio; CI = confidence interval; ASCT = autologous stem cell transplantation; CR = complete response; PET = positron emission tomography.
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Other factors with an impact on survival were an increased need for RBC and platelet unit transfusions, as well as the duration of grade 4 thrombocytopenia. Patient selection criteria as well as the treatment underwent a practice change during the last ten years at our institution.
Figure 4
Impact of pre-and post-transplantation PET/CT on event free survival (A, C) and overall survival (B, D) in all patients. Pretransplantation PET/CT was done during or after induction chemotherapy, post-transplantation PET/CT was done within 3 months after ASCT.
Figure 5
Impact of pre-transplantation PET/CT on event free and overall survival according to lymphoma entity. Hodgkin's lymphoma (A, B) and DLBCL (C, D).
Until 2005, patients received predominantly CBV as conditioning regimen, but from 2006 on BEAM was the preferred regimen due to its more favourable toxicity profile [18] [19] [20] . As a result of the optimisation of the transplant procedure and the supportive care measures, the indication for ASCT was continuously expanded, especially in patients suffering from DLBCL. As a consequence, older patients with more advanced DLBCL were increasingly selected for autotransplant during the observation period. In fact, the difference in patient age reached almost statistical significance and may explain the worse survival for the DLBCL patients who were autotransplanted from 2006 on. Another factor that may have impacted negatively on patient outcome in our study is the prior exposure to rituximab, since only a few patients had been pre-treated in the early period and most patients had received prior ritux-
Figure 6
Impact of post-transplantation PET/CT on event free survival (A) and overall survival (B) in DLBCL patients. imab in the late period. Several studies have shown that rituximab during first line treatment was associated with worse survival in relapsing patients [21, 22] . In summary, the observed outcome of the patients receiving ASCT after BEAM is comparable to the results presented in the Collaborative Trial in Relapsed Aggressive Lymphoma (CORAL), confirming these data also in the daily practice outside of a clinical trial [21] . The low mortality rates after ASCT highlight that the impact on survival is not due to toxicities and subsequent differences in short-term outcome after transplantation, but rather due to patient heterogeneities [21, 23] .
The most relevant risk factor identified in our study was the initial lymphoma stage. This finding confirms its established role as the main prognostic factor for patient outcome. Accordingly, lymphoma stage nowadays is the basis for a risk-adapted treatment decision, either directly in HL patients, or indirectly via the IPI score in DLBCL patients [24] . Increasing numbers of previous chemotherapy lines before ASCT were associated with worse survival. This may be explained by the lower chemosensitivity and more aggressive course of the underlying disease, which renders it prognostically disadvantageous [25, 26] . This is also supported by our observation that patients with primary refractory disease had a lower survival rate than patients with relapsed disease. Another important finding of our analysis was the impact of the PET/CT in the ASCT setting. A PET/CT with persistent pathologic FDG-uptake during or after salvage chemotherapy was associated with reduced EFS and OS. In addition, a positive PET/CT within 3 months after ASCT was also associated with a worse outcome. For the patient subgroup with DLBCL alone, a positive PET/CT before and after ASCT was associated with inferior EFS, but only a trend for inferior OS was seen. For the HL patient subgroup, no statistically meaningful differences were seen. The lack of statistically significant differences for survival in the subgroup analyses may be explained by the low number of events in our patient cohort, since, especially HL patients, had a very favourable long-term disease free time and overall survival rate. Only very few HL patients had persistent FDG-avid lesions in the PET/CT after ASCT, thus preventing a statistically meaningful analysis. On the other hand, one could argue, based on these data, that patients with HL benefit more from high dose therapy than DLBCL patients, even if the lymphoma cells show residual FDG-uptake before transplantation. A few other studies have reported on the impact of PET positivity before [27] [28] [29] [30] [31] [32] and after [33, 34] ASCT in lymphoma patients, and are in line with our findings. We hypothesise, based on these results that pre-and post-transplantation PET/CT may be a useful prognostic marker for lymphoma patients.
In our risk factor analysis we found a correlation of increased requirement for RBC and platelet unit transfusions (and length of grade 4 thrombocytopenia, respectively) with survival. Transfusion of RBC or platelets was an adverse risk factor for OS, but not EFS. Interestingly, an increased need for RBC transfusions has also been linked to adverse outcome in patients undergoing cardiac surgery or surgery for hip fracture [35] [36] [37] . In the ASCT setting of lymphoma patients, the presence of anaemia has been identified as an independent risk factor for survival [38] , but the influence of the number of blood product transfusions on the long-term outcome has not been broadly reported. It is not clear, however, whether the increased need for blood products correlates with an increased long-term risk of death due to immunomodulation or induction of chronic inflammatory events, or whether it is just reflecting a prognostically unfavourable, more severely ill patient subgroup with reduced bone marrow function in need for transfusions.
The main limitations of our study are its retrospective nature and the limited patient number. Retrospective evaluation of data is often hindered by missing or inadequate documentation. However, most of the individual data have been originally coded prospectively, and we are reporting on all consecutive patients transplanted during the evaluated time period, thus avoiding any form of selection bias. Another limitation may be that our patients came from one area of Switzerland and the results may therefore not be generalisable to the whole of Switzerland and other countries. Finally, since many patients had been initially pretreated at other hospitals and the treatment had not been predefined, differences in first line chemotherapy regimens may have influenced the subsequent response to ASCT and consequently the survival rates.
In conclusion, the long-term survival data of our patients with HL and NHL are in agreement with the existing literature indicating treatment with international quality standards. Both CBV and BEAM are effective conditioning regimens for lymphoma patients. Most importantly, we present an out-of-study confirmation of the recently published CORAL data by demonstrating similar efficacy of BEAM as conditioning regimen followed by ASCT in patients with DLBCL. Responsiveness to primary chemotherapy, initial lymphoma stage, the amount of pre-treatment, and a PET/CT scan before and after ASCT are prognostic for survival. Interestingly, an increased need for blood product transfusions during the post-transplant period is associated with a higher risk for reduced survival in our patients. Our results may lay the foundation for further research in wider populations before specific treatment recommendations can be finally derived. 
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